An Observational Study to Assess the Protocol for the COVID-19 Treatment in Burkina Faso

All patients who received one of the two combinations will be included in the study and
followed-up until the patient is discharged from the hospital. They will be seen daily during
the period of their active clinical follow-up at the hospital. At each visit, the medical
history since the last visit (including treatments taken), signs and symptoms in progress if
any, will be collected. A nasopharyngeal swab will be collected on Day 0, 3, 7 and 14 and
then on day 21 if he is still positive in order to assess the evolution of the viral load.
However if until the end of the follow-up on D21 the test is still positive, the sampling
will be continued until the patient become negative as recommended by the national standard
of care for the Covid patients management in Burkina Faso.

In terms of safety, an ECG will be performed on day 0 prior to the treatment administration
and this will be repeated on day 7 and day 14 and every week until it normalizes or the
patient will be recommended to see a cardiologist to check the normalization of his ECG after
discharge from hospital. Adverse events will be recorded including biological parameters
(biochemistry and hematology) will be monitored, as well as changes in relevant laboratory
parameters.